قصة عود 100 مل
وفر 26%! اشترِ قصة عود 100 مل بسعر 159.36 د.ل فقط في ليبيا. متوفر حالياً، الدفع
🛒 تسوق الآنDina Mosallem Appointed Business Unit Director for Pharma at MSD
Veteran pharmaceutical executive takes leadership role covering Gulf, Libya, and Egypt markets with 14 years of commercial experience
Dina Mosallem has been appointed Business Unit Director, Pharma – Gulf, Libya & Egypt at MSD, one of the world's leading pharmaceutical companies, bringing more than 14 years of commercial and medical affairs experience to the role. The appointment, announced today, marks a significant leadership expansion across three of the region's most strategically important healthcare markets.
Mosallem's new position places her at the helm of MSD's pharmaceutical business operations spanning the Gulf Cooperation Council states, Libya, and Egypt — a combined market serving over 150 million people with rapidly evolving healthcare infrastructure and growing demand for innovative therapies.
A Proven Track Record in Regional Pharma Leadership
According to HR Today, Mosallem brings deep expertise in pharmaceutical commercial strategy, having spent over a decade navigating complex regulatory environments and building high-performing teams across the Middle East and North Africa region. Her career trajectory reflects a consistent pattern of leadership in medical training, product launches, and cross-functional business development.
Prior to this appointment, Mosallem held progressively senior roles within the pharmaceutical sector, with documented experience in medical information management, pre-launch preparation for new products, and regulatory support — skills that are particularly critical in markets like Libya where healthcare systems are undergoing significant modernization efforts.
Key Facts About the Appointment
- Executive: Dina Mosallem — Business Unit Director, Pharma – Gulf, Libya & Egypt
- Company: MSD (Merck Sharp & Dohme) — global pharmaceutical leader
- Experience: More than 14 years in commercial and medical affairs
- Markets Covered: Gulf states, Libya, and Egypt
- Announcement Date: Today, via HR Today and CXO Lanes MENA
- Regional Context: META region (Middle East, Turkey, Africa) pharmaceutical expansion
Regional Medical Leadership Context
The appointment comes amid broader leadership restructuring at MSD's META operations. Tamer Elfishawy, Regional Medical Director META, has been overseeing medical affairs across the region, with responsibilities spanning medical training programs, medical information systems, and pre-launch preparation for new pharmaceutical products. Mosallem's commercial leadership role complements this medical affairs structure, creating an integrated leadership approach for the region.
LinkedIn professional network data shows 12 comments on the CXO Lanes MENA announcement, reflecting strong industry interest in the appointment across the regional pharmaceutical community.
Why This Matters for Libya
Libya's pharmaceutical market is valued at over $1.5 billion annually, with the country relying heavily on imported medicines to meet the needs of its 7 million citizens. The appointment of a dedicated business unit director with explicit Libya coverage signals MSD's commitment to strengthening its presence in the Libyan market — a positive development for healthcare access in the country.
Libya currently faces significant challenges in pharmaceutical supply chains, with many essential medicines experiencing periodic shortages. Having a senior executive with direct responsibility for the Libyan market could accelerate the introduction of innovative therapies and improve distribution networks across the country's healthcare facilities.
The Libyan pharmaceutical sector has been gradually recovering, with increased government health spending and growing partnerships with international healthcare companies. MSD's expanded leadership presence aligns with broader trends of multinational pharmaceutical companies investing in North African markets.
Looking Ahead
Mosallem's appointment reflects a growing trend of experienced regional talent taking on expanded leadership roles within multinational pharmaceutical companies operating in the Middle East and North Africa. Her 14 years of commercial experience position her to drive growth across three diverse but interconnected markets.
As Libya continues to rebuild its healthcare infrastructure, leadership appointments like this one carry significance beyond corporate restructuring — they represent tangible commitments to improving pharmaceutical access and bringing innovative treatments to patients across the region.
— LibyaPress / Health Desk
===END_ENGLISH===